Rosomidnar liposomal

Drug Profile

Rosomidnar liposomal

Alternative Names: PNT-2258

Latest Information Update: 11 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ProNAi Therapeutics
  • Developer Sierra Oncology
  • Class Antineoplastics; Oligonucleotides
  • Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Non-Hodgkin's lymphoma
  • Suspended Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma
  • No development reported Solid tumours

Most Recent Events

  • 09 Jan 2017 ProNAi Therapeutics is now called Sierra Oncology
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Infusion)
  • 06 Jun 2016 Suspended - Phase-II for Chronic lymphocytic leukaemia (for Richter's transformation) in USA, United Kingdom, Hungary (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top